Studying the Safety and Effectiveness of an Investigation

Recruiting

18 years - 80 years

All

24 participants needed

1 Location

Brief description of study

The purpose of Part A of this study is to evaluate the safety, tolerability, and cardiac pharmacodynamics (the effect of the study drug on your heart) of the study drug, danicamtiv, when administered by mouth twice a day for approximately one to two weeks. Part A which may last between 4 and 11 weeks, and an optional Part B which may last up to about 104 weeks.

Detailed description of study

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Heart, Dilated Cardiomyopathy
Age: 18 years - 80 years
Gender: All

Ages 18 to 80 Diagnosed with Dilated Cardiomyopathy (DCM) due to a mutation in either MYH7 or TTN, both of which are genes involved in the function of heart muscle.

Updated on 04 Aug 2024. Study ID: 848993

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Studying the Safety and Effectiveness of an Investigation Drug Danicamtiv in Patients with Dilated Cardiomyopathy

Brief description of study

Detailed description of study

Eligibility of study

Find a site

Interested in the study